Published in N Engl J Med on November 30, 1995
Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol (2009) 3.33
Quantifying data quality for clinical trials using electronic data capture. PLoS One (2008) 2.19
Surgery for early breast cancer--can less be more? N Engl J Med (1995) 1.39
Surgery and radiotherapy for early breast cancer. BMJ (1995) 1.15
What can we learn from a decade of database audits? The Duke Clinical Research Institute experience, 1997--2006. Clin Trials (2009) 0.97
Tumor bed volumetric changes during breast irradiation for the patients with breast cancer. Radiat Oncol J (2013) 0.87
Breast cancer in young women: special considerations in multidisciplinary care. J Multidiscip Healthc (2014) 0.87
Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care. CMAJ (1999) 0.84
Isolated ipsilateral nipple recurrence: important lessons to learn. Malays J Med Sci (2011) 0.75
The effects of fraud on the evaluation of health care. Health Care Anal (2005) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
Predictive margins with survey data. Biometrics (1999) 9.18
Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science (1991) 6.12
Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 5.18
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Asthma and air pollution in the Los Angeles area. Am J Public Health (1980) 4.02
Retracted Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol (1990) 3.76
Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol (1993) 3.51
Natural selection of life history attributes: an analytical approach. Theor Popul Biol (1974) 3.50
Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst (1999) 3.35
Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst (1999) 3.25
Cytokine production at the site of disease in human tuberculosis. Infect Immun (1993) 3.04
Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J Immunol (1992) 3.03
Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol (2001) 2.82
Methods for analyzing panel studies of acute health effects of air pollution. Biometrics (1979) 2.76
Modelling the sampling design in the analysis of health surveys. Stat Methods Med Res (1996) 2.74
IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol (1992) 2.67
T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun (1995) 2.57
Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst (1996) 2.12
High-dose chemotherapy for breast cancer. Ann Intern Med (1996) 2.09
Representation of older patients in cancer treatment trials. Cancer (1994) 2.06
Assigning care costs associated with therapeutic oncology research: a modest proposal. J Natl Cancer Inst (1992) 2.01
Cytokine control of parasite-specific anergy in human lymphatic filariasis. Preferential induction of a regulatory T helper type 2 lymphocyte subset. J Clin Invest (1993) 2.00
Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J Immunol (1993) 2.00
Gamma delta T lymphocytes in human tuberculosis. J Infect Dis (1992) 1.78
Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med (1999) 1.77
Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med (1991) 1.77
Determination of microgram quantities of protein in the presence of milligram levels of lipid with amido black 10B. Anal Biochem (1985) 1.75
Patterns of cytokine production by mycobacterium-reactive human T-cell clones. Infect Immun (1993) 1.72
Regulation of parasite-induced eosinophilia: selectively increased interleukin 5 production in helminth-infected patients. J Exp Med (1990) 1.71
Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol Appl Pharmacol (1986) 1.70
Survey inference for subpopulations. Am J Epidemiol (1996) 1.69
Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol (1995) 1.69
Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J Exp Med (1996) 1.68
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 1.67
Activation of mouse T-helper cells induces abundant preproenkephalin mRNA synthesis. Science (1986) 1.60
Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen. Cytokine detection by immunoassay and intracellular immunostaining. J Immunol Methods (1993) 1.60
Retinoids in cancer therapy. J Clin Oncol (1992) 1.59
Choice of column scores for testing independence in ordered 2 X K contingency tables. Biometrics (1987) 1.59
Increasing incidence of right-sided lesions in colorectal cancer. Am J Surg (1979) 1.58
Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol (1997) 1.56
Selecting drug combinations based on total equivalent dose (dose intensity) J Natl Cancer Inst (1990) 1.56
Data monitoring committees and interim monitoring guidelines. Control Clin Trials (1999) 1.55
High levels of spontaneous and parasite antigen-driven interleukin-10 production are associated with antigen-specific hyporesponsiveness in human lymphatic filariasis. J Infect Dis (1996) 1.51
A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on Interferon gamma production. J Exp Med (2001) 1.48
Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest (1993) 1.47
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. J Clin Oncol (1989) 1.46
Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol (1993) 1.44
Cytokine mRNA in the central nervous system of SCID mice infected with Toxoplasma gondii: importance of T-cell-independent regulation of resistance to T. gondii. Infect Immun (1993) 1.44
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer (2009) 1.44
Regulation of immunoglobulin (Ig)E synthesis in the hyper-IgE syndrome. J Clin Invest (1990) 1.42
Analyzing health surveys for cancer-related objectives. J Natl Cancer Inst (1999) 1.42
Comorbid psychopathology in binge eating disorder: relation to eating disorder severity at baseline and following treatment. J Consult Clin Psychol (2000) 1.40
IL-4- and IL-5-secreting lymphocyte populations are preferentially stimulated by parasite-derived antigens in human tissue invasive nematode infections. J Immunol (1993) 1.39
APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif. J Immunol (1999) 1.38
Expression of murine and human granulocyte-macrophage colony-stimulating factors in S. cerevisiae: mutagenesis of the potential glycosylation sites. EMBO J (1986) 1.36
Functional heterogeneity among human inducer T cell clones. J Immunol (1988) 1.34
Parallel regulation of IL-4 and IL-5 in human helminth infections. J Immunol (1992) 1.33
Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer (1993) 1.31
Impingement syndrome in the absence of rotator cuff tear (stages 1 and 2). Orthop Clin North Am (1987) 1.30
Importance of the carrier state as a source of Staphylococcus aureus in wound sepsis. J Hyg (Lond) (1969) 1.29
A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol (1989) 1.28
Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst (1992) 1.28
COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth. Science (1989) 1.27
Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer (1986) 1.26
Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev (1988) 1.25
The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24
The significance of a "positive" rectal examination in acute appendicitis. Dis Colon Rectum (1979) 1.24
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Thalamo-cortical processing of vibrissal information in the rat. I. Intracortical origins of surround but not centre-receptive fields of layer IV neurones in the rat S1 barrel field cortex. J Comp Neurol (1991) 1.21
Censoring distributions as a measure of follow-up in survival analysis. Stat Med (1986) 1.21
Primary hepatocellular cancer--present results and future prospects. Int J Radiat Oncol Biol Phys (1983) 1.20
Apical root resorption in orthodontically treated adults. Am J Orthod Dentofacial Orthop (1996) 1.19
Sensitive protein assay in presence of high levels of lipid. Methods Enzymol (1989) 1.19
Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol (1992) 1.18
Antibody against interleukin-6 reduces inflammation and numbers of cysts in brains of mice with toxoplasmic encephalitis. Infect Immun (1994) 1.18
Development of polyclonal and monoclonal antibodies for immunoassay and neutralization of human interleukin-4. J Immunol Methods (1989) 1.17
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol (1990) 1.17
Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. Am Rev Respir Dis (1991) 1.17
Effective sample sizes for confidence intervals for survival probabilities. Stat Med (1987) 1.15
Induction of human IgE synthesis by CD4+ T cell clones. Requirement for interleukin 4 and low molecular weight B cell growth factor. J Exp Med (1989) 1.14
Antineoplastic activity of cannabinoids. J Natl Cancer Inst (1975) 1.14
Morphologic effect of dimethyl sulfoxide on the blood-brain barrier. Science (1982) 1.14
Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J Neurochem (1995) 1.13
Fractalkine protein localization and gene expression in mouse brain. J Neurosci Res (2003) 1.11
Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J Natl Cancer Inst (1987) 1.10
Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst (1989) 1.10
Early expression of cytokines in lymph nodes after treatment in vivo with Staphylococcus enterotoxin B. J Immunol Methods (1994) 1.10
The yeast mitochondrial citrate transport protein. Probing the roles of cysteines, Arg(181), and Arg(189) in transporter function. J Biol Chem (2000) 1.09
Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res (1984) 1.09
Accrual to clinical trials. J Natl Cancer Inst (1988) 1.09
1991 national survey of carcinoma of the breast by the Commission on Cancer. J Am Coll Surg (1994) 1.09
Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology (1993) 1.09
IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. Am Rev Respir Dis (1993) 1.08
National Cancer Institute's evaluation of unconventional cancer treatments. J Natl Cancer Inst (1992) 1.08
Immunocytochemical detection of cytokines in the lymph nodes and brains of mice resistant or susceptible to toxoplasmic encephalitis. J Infect Dis (1994) 1.08